betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer
- PMID: 20501838
- DOI: 10.1158/0008-5472.CAN-09-4487
betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer
Abstract
Advanced non-small cell lung cancer (NSCLC) has a dismal prognosis. betaIII-Tubulin, a protein highly expressed in neuronal cells, is strongly associated with drug-refractory and aggressive NSCLC. To date, the role of this protein in in vivo drug resistance and tumorigenesis has not been determined. NSCLC cells stably expressing betaIII-tubulin short hairpin RNA displayed reduced growth and increased chemotherapy sensitivity when compared with control clones. In concordance with these results, stable suppression of betaIII-tubulin reduced the incidence and significantly delayed the growth of tumors in mice relative to controls. Our findings indicate that betaIII-tubulin mediates not only drug sensitivity but also the incidence and progression of lung cancer. betaIII-Tubulin is a cellular survival factor that, when suppressed, sensitizes cells to chemotherapy via enhanced apoptosis induction and decreased tumorigenesis. Findings establish that upregulation of a neuronal tubulin isotype is a key contributor to tumor progression and drug sensitivity in lung adenocarcinoma.
Similar articles
-
Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.Cancer Res. 2007 Oct 1;67(19):9356-63. doi: 10.1158/0008-5472.CAN-07-0509. Cancer Res. 2007. PMID: 17909044
-
The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.Oncol Rep. 2005 Aug;14(2):421-4. Oncol Rep. 2005. PMID: 16012725
-
MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.Oncogene. 2006 Jun 1;25(23):3335-45. doi: 10.1038/sj.onc.1209364. Epub 2006 Feb 6. Oncogene. 2006. PMID: 16462770
-
The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.Lung Cancer. 2010 Feb;67(2):136-43. doi: 10.1016/j.lungcan.2009.09.007. Epub 2009 Oct 13. Lung Cancer. 2010. PMID: 19828208 Review.
-
[Class III beta tubulin expression in nonsmall cell lung cancer].Rev Mal Respir. 2010 Apr;27(4):383-6. doi: 10.1016/j.rmr.2010.03.006. Epub 2010 Mar 25. Rev Mal Respir. 2010. PMID: 20403547 Review. French.
Cited by
-
PM534, an Optimized Target-Protein Interaction Strategy through the Colchicine Site of Tubulin.J Med Chem. 2024 Feb 22;67(4):2619-2630. doi: 10.1021/acs.jmedchem.3c01775. Epub 2024 Jan 31. J Med Chem. 2024. PMID: 38294341 Free PMC article.
-
Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer.Am J Cancer Res. 2015 May 15;5(6):1862-77. eCollection 2015. Am J Cancer Res. 2015. PMID: 26269749 Free PMC article.
-
Sulforaphane metabolites inhibit migration and invasion via microtubule-mediated Claudins dysfunction or inhibition of autolysosome formation in human non-small cell lung cancer cells.Cell Death Dis. 2019 Mar 15;10(4):259. doi: 10.1038/s41419-019-1489-1. Cell Death Dis. 2019. PMID: 30874545 Free PMC article.
-
Gene expression analysis of SCC tumor cells in muscle tissue.Eur Arch Otorhinolaryngol. 2012 Jun;269(6):1653-63. doi: 10.1007/s00405-011-1799-0. Epub 2011 Oct 15. Eur Arch Otorhinolaryngol. 2012. PMID: 22002462
-
Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.Oncotarget. 2015 May 20;6(14):12020-34. doi: 10.18632/oncotarget.2664. Oncotarget. 2015. PMID: 25557168 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical